|
Real-time Estimate
Cboe Europe
11:30:00 2026-09-04 am EDT
|
5-day change | 1st Jan Change | ||
| 1,844.75 GBX | -1.17% |
|
-0.40% | +1.18% |
| Sep. 03 | Global markets live: Apple, Microsoft, Tesla, Google, Uber… |  |
| Sep. 03 | Haleon Negotiates Better Shelf Placement at Walmart, Target | MT |
| Market Cap | 74.79B 101B 87.11B 81.75B 140B 9,571B 141B 967B 377B 4,891B 380B 372B 15,752B | P/E 2026 * |
14.1x | P/E 2027 * | 11.6x |
|---|---|---|---|---|---|
| Enterprise Value | 94.63B 128B 110B 103B 177B 12,109B 178B 1,224B 476B 6,188B 481B 471B 19,930B | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.59x |
| Free-Float |
92.75% | Yield 2026 * |
3.73% | Yield 2027 * | 4.02% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
OTC Markets
| GLAXF | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript : GSK plc
| Sep. 03 | Wall Street's Triple Squeeze | |
| Sep. 02 | GSK plc : Deutsche Bank reiterates its Neutral rating | ZD |
| Sep. 01 | GSK plc : JP Morgan gives a Sell rating | ZD |
| Aug. 25 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 20 | Cancer vaccines finally garner the spotlight |  |
| 1 day | -1.08% | ||
| 1 week | -0.62% | ||
| Current month | -0.62% | ||
| 1 month | -3.79% | ||
| 3 months | -3.15% | ||
| 6 months | -12.91% | ||
| Current year | +0.96% |
| 1 week | 1,835.5 |  | 1,911 |
| 1 month | 1,803 | | 1,972 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,445 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/24/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -28,978 | 0.0007% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -49 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.11% | -0.62% | +25.39% | +34.10% | 101B | |
| -1.31% | -2.55% | +54.08% | +105.07% | 1,034B | |
| -0.91% | +2.69% | +53.98% | +71.31% | 671B | |
| -1.24% | +0.64% | +20.71% | +75.98% | 460B | |
| +0.04% | -0.59% | +29.34% | +38.40% | 353B | |
| -1.10% | +4.96% | +24.98% | +45.88% | 309B | |
| -1.12% | +0.30% | -1.49% | +12.31% | 255B | |
| -1.46% | +1.14% | +56.14% | +72.18% | 240B | |
| -0.88% | +1.30% | -16.96% | -54.33% | 207B | |
| -0.69% | +3.12% | +33.21% | +99.87% | 188B | |
| Average | -0.95% | +1.22% | +27.94% | +50.08% | 381.8B | |
| Weighted average by Cap. | -1.00% | +1.04% | +36.17% | +65.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 45.94B 39.52B 37.09B 63.33B 4,342B 63.84B 439B 171B 2,219B 172B 169B 7,147B | 35.49B 48.04B 41.34B 38.79B 66.24B 4,542B 66.77B 459B 179B 2,321B 180B 176B 7,475B |
| Net income | 5.42B 7.34B 6.32B 5.93B 10.12B 694B 10.2B 70.11B 27.3B 355B 27.56B 26.96B 1,142B | 6.47B 8.76B 7.53B 7.07B 12.07B 828B 12.17B 83.63B 32.57B 423B 32.88B 32.16B 1,362B |
| Net Debt | 19.84B 26.85B 23.11B 21.68B 37.03B 2,539B 37.32B 257B 99.89B 1,297B 101B 98.65B 4,178B | 17.06B 23.09B 19.87B 18.65B 31.84B 2,183B 32.09B 221B 85.9B 1,116B 86.72B 84.83B 3,593B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | GBX 1,846.00 | -1.10% | 1,357,707 |
| 26-09-03 | GBX 1,866.50 | +0.27% | 4,089,944 |
| 26-09-02 | GBX 1,861.50 | -0.53% | 4,977,854 |
| 26-09-01 | GBX 1,871.50 | +0.97% | 4,720,553 |
| 26-08-28 | GBX 1,853.50 | +0.08% | 7,790,314 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
